CD19 and neoplasm: These two signatures outperformed all previously identified tumor biomarkers, including CD19 expression, individual genes, and B-cell signature, and provide biological insights into factors influencing CAR T-cell outcome, which could be informative for risk stratification and the development of next-generation CAR T-cell products.